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Vitreoscilla hemoglobin (VHb) is accumulated at high levels in both soluble and insoluble forms when
expressed from its native promoter on a pUC19-derived plasmid in Escherichia coli. Examination by atomic
absorption spectroscopy and electron paramagnetic resonance spectroscopy revealed that the insoluble form
uniformly lacks the heme prosthetic group (apoVHb). The purified, soluble form contains heme (holoVHb) and
is spectroscopically indistinguishable from holoVHb produced by VitreosciMla cells. This observation suggested
that a relationship may exist between the insolubility of apoVHb and biosynthesis of heme. To examine this
possibility, a series of experiments were conducted to chemically and genetically manipulate the formation and
conversion of 5-aminolevulinic acid (ALA), a key intermediate in heme biosynthesis. Chemical perturbations
involved supplementing the growth medium with the intermediate ALA and the competitive inhibitor levulinic
acid which freely cross the cell barrier. Genetic manipulations involved amplifying the gene dosage for the
enzymes ALA synthase and ALA dehydratase. Results from both levulinic acid and ALA supplementations
indicate that the level of soluble holoVHb correlates with the heme level but that the level of insoluble apoVHb
does not. The ratio of soluble to insoluble VHb also does not correlate with the level of total VHb accumulated.
The effect of amplifying ALA synthase and ALA dehydratase gene dosage is complex and may involve secondary
factors. Results indicate that the rate-limiting step of heme biosynthesis in cells overproducing VHb does not
lie at ALA synthesis, as it reportedly does in wild-type E. coli (S. Hino and A. Ishida, Enzyme 16:42-49, 1973).
Many heterologous proteins aggregate intracellularly when
expressed in recombinant hosts (11, 21, 23). This phenomenon
is best documented for protein expression in the gram-negative
bacterial host Escherichia coli. However, it is not confined
exclusively to this bacterium or for that matter to prokaryotic
hosts (16, 25). The mechanisms underlying this intracellular
aggregation are not well understood and may vary with pro-
tein, expression construct, and host. A common theme, how-
ever, appears to be malfunction or disruption of intracellular
protein folding. Mitraki and King (21) have reviewed the ways
that intracellular protein folding may malfunction and lead to
insolubility.
Vitreoscilla hemoglobin (VHb) is a soluble homodimeric
heme protein expressed by the obligate aerobic bacterium
Vitreoscilla sp. in response to low oxygen concentration (24).
This protein can be expressed from its native promoter in
recombinant E. coli under similar hypoxic conditions (3, 12-
14). VHb is accumulated concurrently in both soluble and
insoluble forms when expressed in E. coli from a high-copy-
number pUC19-derived plasmid under the control of its native
promoter (7). The soluble form is found to partition between
the cytoplasmic and periplasmic spaces despite the absence of
a processed N-terminal signal peptide (15). Similar compart-
mentalization is observed in the native host Vitreoscilla sp. The
insoluble form accumulated in E. coli is only found aggregated
in cytoplasmic inclusion bodies (7). The principal contami-
nants of VHb inclusion body preparations are derived from
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cell wall debris which cosediment with inclusion bodies during
centrifugation (7).
In their insightful review, Mitraki and King discussed the
role of cofactors in protein folding and speculated that their
absence during in vivo protein folding could lead to aggrega-
tion and inclusion body formation (21). Accordingly, one might
expect apoprotein (protein lacking its necessary cofactor)
aggregation whenever the ratio of net polypeptide synthetic
rate to net cofactor synthetic rate exceeds their stoichiometric
binding ratio. Such a state would arise if the cofactor biosyn-
thetic pathway enzymes were saturated at maximal values and
consequently unable to respond to a demand for increased
flux. In the present case involving a heme protein, one would
expect simultaneous accumulation of soluble and insoluble
proteins with the two forms distinguishable by their heme
contents.
Comparison between the VHb polypeptide accumulation
rate and the reported enhanced E. coli heme accumulation rate
(8, 10) suggests that the inadequate biosynthesis of heme may
be involved in the insolubility of VHb in vivo. Soluble VHb
accumulates during stationary phase when expressed in E. coli
at a fairly constant rate of 0.2 ,umol/g (dry wt)/h to a final
concentration of 3.0 ,umol/g (dry wt), which represents approx-
imately 10% of total protein. This rate is consistent with
previous analyses which indicate that under favorable condi-
tions E. coli is capable of synthesizing approximately 0.2 ,umol
of heme per g (dry wt) per h during stationary phase (10).
Accumulation of insoluble VHb during stationary phase varies
but is generally highest, approximately 0.5 ,umol/g (dry wt)/h,
during phases exhibiting the accumulation of metabolic acids.
In this study we investigate the biosynthetic limitation of heme
as a possible mechanism for the in vivo aggregation of the
insoluble form of VHb lacking the heme prosthetic group
(apoVHb). The relationship between heme content and in vivo
solubility was analyzed by physical characterization of the
soluble and insoluble forms of VHb. The relationship between
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the biosynthetic activity of heme and the insolubility of VHb
was investigated by genetic and chemical perturbation of the
relative rates of polypeptide and heme syntheses. Such inves-
tigations may prove to be generally useful for recombinant
expression of cofactor-requiring proteins.
MATERIALS AND METHODS
Bacterial strains and plasmids. E. coli JM101 with the
genotype [supE thi A(lac-proAB) F' traD36 proAB lacIq
AlacAM15] was used as the host strain throughout (26).
Plasmid pRED2 was constructed from pUC19 (26) by insertion
of a 2.2-kb HindlIl fragment which contains the vhb gene
under the control of its native promoter (12). Plasmid pVSP1
was constructed from pRED2 by insertion of a 2.9-kb BamHI-
HindlIl fragment isolated from pJL68 (17, 18) which contains
the hemA gene under the control of its native promoter.
Plasmid pVDP1 was constructed from pRED2 by insertion of
a 1.6-kb PstI fragment isolated from pJL2 (20) which contains
the hemB gene under the control of its native promoter. The
hemA and vhb genes in pVSP1 were in the same orientation,
while the hemB and vhb genes in pVDP1 were in the opposite
orientation.
Media and growth conditions. Phosphate-buffered LB me-
dium (10 g of Bacto Tryptone per liter, 5 g of Bacto Yeast
Extract per liter, 5 g of NaCl per liter, 3 g of K2HPO4 per liter,
1 g of KH2PO4 per liter; pH 7) supplemented with 100 ,ug of
ampicillin per ml was used as the basal medium in all cases. For
atomic absorption spectroscopy, cells were grown by a fed-
batch procedure, harvested, washed, lysed, and fractionated by
differential centrifugation, using methods described previously
(7). For heme perturbation studies, capped side-arm shake
flasks (300 ml; Belco) containing 50 ml of medium were
inoculated with 0.5 ml of a culture grown overnight and shaken
at 250 rpm in a rotary shaker (New Brunswick) at 37°C. When
the absorbance (Klett 54 filter) of the culture reached 150 Klett
units, cells were harvested by centrifugation at 37°C and
resuspended in prewarmed fresh medium to the same absor-
bance. The resulting stock culture was then aliquoted into
culture tubes (Kimax; 16 by 150 mm) to a 5-ml volume and
grown in a reciprocating water bath shaker (Reichert-Jung) at
150 cycles per min and 37°C. Culture tubes were used for VHb
induction to ensure uniform microaerobic conditions necessary
for controlled activation of the vhb promoter. All cells lacked
VHb at the time of tube inoculation as determined by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and difference absorption spectroscopy (<0.06 ,umol/g
[dry wt]). Culture tubes were supplemented as indicated with
either levulinic acid or 5-aminolevulinic acid (ALA) from
neutral-pH 1 M stock solutions and incubated for 12 h. All
cultivations and analyses were conducted in duplicate. A Klett
absorbance cell density of 150 is obtained in shake flask
cultivation during late exponential growth of all cultures
investigated. Test tube cultures grown from colony inoculation,
however, reach a cell density of only 150 Klett units in late
stationary phase, presumably because of oxygen transfer limi-
tations. Cell growth in culture tubes inoculated with stock
culture having a cell density of 150 Klett units is consequently
considered microaerobic.
Atomic absorption spectroscopy sample preparation. Insol-
uble lysate fractions were obtained from late-stationary-phase
cultures having the same optical density. Stocks were prepared
from the insoluble lysate fraction by washing the fraction
extensively with 50 mM potassium phosphate (pH 7.0)-10 mM
EDTA followed by washing and resuspension in 50 mM
potassium phosphate (pH 7.0). The resulting JM101::pRED2
debris stock contained approximately 0.5 mM VHb polypep-
tide, as determined by quantitative SDS-PAGE. Resulting E.
coli JM101::pUC19 debris stock contained the same amount of
cell wall material, as judged by the levels of the outer mem-
brane proteins OmpA, OmpF, and OmpC. Inclusion body
analogs were prepared by titrating purified VHb stock into
JM101::pUC19 debris stock to achieve a protein composition
comparable to that of JM101::pRED2 debris stock. VHb was
purified from the soluble lysate fraction of JM101::pRED2 by
previously described procedures (5). The concentration of
VHb in purified stock solutions was determined by amino acid
analysis and difference absorption spectroscopy.
Atomic absorption spectroscopy. Cell debris stocks, purified
VHb stock, and inclusion body analogs were prepared for
analysis by one of two methods. In the first method, samples
were diluted with ultrapure HCl (Baker Ultrex Ultrapure HCl)
and glass-distilled water to give a final HCI concentration of 1.2
N. In the second method, samples were hydrolyzed by vapor-
phase hydrolysis in constantly boiling HCl at 165°C for 1 h,
resuspended in 1.2 N Ultrapure HCl, and filtered through
0.22-jim-pore-size filters. Resulting samples were analyzed
with an Instrumentation Laboratory Atomic Absorption Spec-
trometer following the procedures suggested by the Instrumen-
tation Laboratory. Samples analyzed by the first method
systematically gave lower measurements (typically by 20%)
than samples analyzed by the second method. This error is
attributed to a reduced flow rate through the needle orifice for
samples containing particulate matter.
Heme perturbation sample preparation. Following cultiva-
tion, culture density was determined and 3-ml samples were
collected. Cells were isolated by centrifugation, washed with a
solution containing 100 mM Tris-HCl, 50 mM NaCi, 1 mM
EDTA, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl
fluoride, and resuspended in 1 ml of the same solution. Cells
were lysed by sonication on ice with a Heat Systems Ultrasoni-
cator. Soluble and insoluble fractions were separated by cen-
trifugation at 14,000 x g for 5 min. Soluble fractions were
immediately assayed for the soluble form of VHb containing
heme (holoVHb). The total proteins in soluble and insoluble
fractions were separately isolated by 10% trichloroacetic acid
precipitation. Residual trichloroacetic acid was removed with
ethanol-ethyl ether (1:1) washes. Resulting samples were
stored at -70°C for later electrophoresis analysis.
VHb and heme quantitation. Soluble holoVHb levels were
determined by visible absorption spectroscopy of soluble lysate
fractions. The VHb monomer visible difference (carbon mon-
oxide-bound VHb minus reduced VHb) extinction coefficient
[e(VHbCO-VHb at 419 nm)-e(VHbCO-VHb at 437 nm)]
determined by amino acid analysis is 1.067 x 105(M cm)-.
Purified VHb exists naturally in the ferric state, presumably
because of the absence of a reductase present in both Vit-
reoscilla sp. and E. coli (3). The Soret peak of VHb in
examined samples had a maximum at 415 nm, indicating that
the protein was present in the oxygenated state (22). Soluble
and insoluble VHb polypeptide levels were determined by
quantitative SDS-PAGE. Heme levels were determined by the
pyridine hemochromogen assay using visible difference absorp-
tion spectroscopy (4).
Visible difference absorption spectroscopy. Samples were
analyzed with a Shimadzu UV260 spectrophotometer inter-
faced to an IBM-XT computer. Matching 1-cm-path-length
quartz microcuvettes were used with a temperature-controlled
platform maintained at 25°C. Analyses were conducted in 50
mM potassium phosphate (pH 7.0). Reduced VHb was pre-
pared by the addition of sodium dithionite. Carbon monoxide-
bound VHb was prepared by reduction with sodium dithionite
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FIG. 1. Membrane-normalized iron contents of E. coli JMl01::
pUC19 and JMl0l::pRED2 insoluble lysate and inclusion body ana-
logs. Open symbols represent values experimentally determined by
iron analysis of the samples. Filled symbols represent values predicted
from amino acid analysis (circle) and iron analysis (square) of purified
VHb used for analog preparation. Samples were analyzed with (circle)
and without (square) acid hydrolysis pretreatment as described in
Materials and Methods. The units are relative units.
followed by incubation in carbon monoxide at 4 lb/in2 for 30
min. Difference spectra relative to suitable buffer blanks were
obtained in all cases. Serial dilution was used to ensure
linearity of absorbance measurements.
Electrophoresis. SDS-PAGE was conducted with the Bio-
Rad Protein II Multi Cell Electrophoresis system. Resolving
gradient slab gels were composed from 10 to 20% acrylamide,
0.3 to 0.6% bisacrylamide, and 0.1% SDS with a discontinuous
buffer stacking gel. Pellets from soluble and insoluble fractions
were resuspended in sample buffer to a constant biomass
concentration. Gels were run at 32.5 mA per gel and 4°C for 6
h and stained with Coomassie blue. Purified VHb was run as an
internal standard on all gels to correct for variations in
staining. Soluble and insoluble VHb polypeptide concentra-
tions were determined by scanning Coomassie blue-stained
electrophoresis gels with a Molecular Dynamics Computing
Densitometer (Sunnyvale, Calif.). For quantitation, the band-
integrated volume (absorbance intensity integrated over band
area) was determined and the background-integrated volume
(nonspecific background absorbance intensity integrated over
an equal area) was subtracted to give the background-cor-
rected band-integrated volume. The background-corrected
band-integrated volume was then normalized by using the
VHb internal standard to yield an absolute measure of VHb.
All measurements were made within a background-corrected
band-integrated volume range predetermined to vary linearly
with VHb level.
RESULTS
Heme content of VHb inclusion bodies. To determine
whether the soluble and insoluble forms of VHb produced in
E. coli can be distinguished by heme content, the two forms
were analyzed by atomic absorption spectroscopy and electron
TABLE 1. Effect of heme biosynthetic perturbation on
heme accumulation
Amount (,umol/g [dry wtJ) of heme accumulatcd
E. coli strain ALA (mM) Lcvulinic acid (mM)bearing plasmid
0 10 100 0 10 l()(
JMl0l::pUC19 <0.06 <0.06 0.17 <0.06 <0.06 <0.06
JMIO1::pRED2 0.98 1.17 0.68 0.98 1.02 0.66
JM11::pVDP1 0.19 0.31 0.24 0.19 0.17 0.14
JMIO1::pVSPI 1.00 0.82 0.49 1.00 0.62 0.22
paramagnetic resonance spectroscopy. Isolates from the strain
JMIO1::pRED2, which produces VHb from a high-copy-num-
ber pUC19-derived plasmid and the native vhb promoter, were
used because their protein composition has been previously
characterized (7). All E. coli insoluble lysate fractions are
expected to contain iron because of the iron content of
membrane-bound cytochromes. To account for the various
amounts in the membrane among the different samples ana-
lyzed, measurements were normalized by the amount of the
outer membrane proteins OmpA and OmpF. To determine
how much iron would be present if all insoluble VHb con-
tained iron, inclusion body analogs were prepared by titrating
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FIG. 2. Coomassie blue-stained SDS-polyacrylamide gel of lysate
fractions from cells expressing VHb. Soluble (lanes 7, 9, and 11) and
insoluble (lanes 8, 10, and 12) fractions of E. coli JMIOI::pRED2
(lanes 7 and 8), JMIOI::pVSPI (lanes 9 and 10), and JMIOI::pVDPI
(lanes 11 and 12) following induction show the extent of VHb
insolubilization. Comparisons with soluble (lanes 3 and 5) and insol-
uble (lanes 4 and 6) fractions of JM101::pUCl9 (lanes 3 and 4) and
JMIOI::pRED2 (lanes 5 and 6) prior to induction indicate protein
pattern changes accompanying microaerobic incubation. Purified VHb
standard (lane 2) and protein molecular mass markers (lane 1 [94, 67,
43, 30, 20.1, and 14.4 kDa]) are included for reference.
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FIG. 3. Time course of VHb speciation following induction of E. coli JM101::pRED2 (A), JM101::pVDP1 (B) and JM101::pVSP1 (C). The
outside stacked columns show soluble (dark shading) and insoluble (light shading) VHb polypeptide levels determined by SDS-PAGE. The inside
columns show soluble holoVHb levels (stripes) determined by difference absorption spectroscopy.
purified VHb (5) into E. coli JM1O1::pUC19 insoluble lysate.
The iron-to-polypeptide stoichiometry of the purified VHb
stock was determined by amino acid analysis and atomic
absorption spectroscopy to ensure that the titrated iron origi-
nated from VHb.
The membrane-normalized iron contents of E. coli JM101::
pUC19 insoluble lysate, JM1O1::pRED2 insoluble lysate, and
VHb inclusion body analogs are given in Fig. 1. Results show
that purified soluble VHb contains stoichiometric levels of
heme (holoVHb). This is evident because the curves indicating
the iron contents of inclusion body analogs predicted from
purified VHb amino acid analysis and atomic absorption
spectroscopy are coincident. The experimentally determined
iron content of inclusion body analogs is less than that
predicted from purified VHb analysis. This is presumably
caused by a reduced flow rate through the needle orifice for
samples containing particulate matter. Results from analysis of
JM1O1::pRED2 insoluble lysate show that the iron content is at
least sixfold less than expected for lysate containing VHb with
stoichiometric levels of incorporated heme. Further, the mem-
brane-normalized iron content of JM1O1::pRED2 insoluble
lysate is the same as that of JM1O1::pUC19 insoluble lysate.
Each of these observations has been corroborated by electron
paramagnetic resonance spectroscopy (data not shown) and
shows that the insoluble form of VHb produced in JM101::
pRED2 uniformly lacks heme (apoVHb).
Perturbation of heme biosynthesis. To determine if a rela-
tionship exists between the inadequate biosynthesis of heme
and insolubility of VHb in vivo, the synthesis levels of heme
and VHb polypeptide were independently varied. The biosyn-
thetic activity of heme in E. coli overexpressing VHb was
perturbed by chemical and genetic means. The structure of the
putative biosynthetic pathway is described in the Discussion
section of this article. Because the reported rate-limiting step
in heme biosynthesis in E. coli lies at synthesis of ALA, ALA
availability was increased by supplementing the medium. Le-
vulinic acid, a competitive inhibitor of ALA dehydratase, was
used for specific negative perturbation of heme biosynthesis.
Additionally, the gene copy number for the enzyme ALA
synthase, which catalyzes the formation of ALA from gluta-
mate, was amplified by inserting the henmLA structural gene
under the control of its native promoter into the plasmid
pRED2, yielding the plasmid pVSP1. To address a possible
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FIG. 4. Effect of levulinic acid (A) and ALA (B) supplementation
on VHb accumulation by E. coli JM101::pRED2. The outside stacked
columns show soluble (dark shading) and insoluble (light shading)
VHb polypeptide levels determined by SDS-PAGE. The inside col-
umns show soluble holoVHb levels (stripes) determined by difference
absorption spectroscopy.
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FIG. 5. Effect of levulinic acid (A) and ALA (B) supplementation
on VHb accumulation by E. coli JM101::pVDP1. The outside stacked
columns show soluble (dark shading) and insoluble (light shading)
VHb polypeptide levels determined by SDS-PAGE. The inside col-
umns show soluble holoVHb levels (striped) determined by difference
absorption spectroscopy.
limitation in the synthetic activity of porphobilinogen, the copy
number of the gene for the enzyme ALA dehydratase was
amplified by inserting the hemB structural gene under the
control of its native promoter into the plasmid pRED2,
yielding the plasmid pVDP1.
Effect of perturbations on heme accumulation. The de-
scribed perturbations have various effects on heme accumula-
tion as shown in Table 1. High-level expression of VHb in E.
coli itself leads to a dramatic increase (at least 20-fold) in the
accumulation of heme, as evidenced by comparison of heme
levels in cells bearing the plasmids pRED2 and pVSP1 with the
heme level in cells bearing the parent plasmid pUC19. Heme
levels in the former cells reach levels of 1 pumolIg (dry wt).
Heme levels in cells bearing pVDP1, however, are significantly
lower (approximately 0.2 times) than those in cells bearing
either pRED2 or pVSP1 yet are higher than heme levels in
cells bearing pUC19. This trend parallels relative VHb accu-
mulation in these constructs (next section).
Supplementing ALA to cells bearing plasmids pUC19 and
pVDP1 enhances heme accumulation. At moderate concentra-
tion (10 mM), ALA also enhances heme accumulation in
pRED2; however, at higher concentrations (100 mM), it
inhibits heme accumulation. ALA at all concentrations inhibits
heme accumulation in cells bearing pVSP1.
Supplementing levulinic acid leads to inhibition of heme
accumulation in all constructs which express VHb. Cells bear-
ing pVSP1 are most susceptible, showing the highest inhibition
at both moderate (10 mM) and high (100 mM) concentrations.
A concentration of 5 mM levulinic acid is commonly used for
ALA dehydratase inhibition in cell extracts from E. coli (19).
In general, cells bearing pVSP1 behave similarly when the
medium is supplemented with either ALA or levulinic acid,
exhibiting increased inhibition with increasing concentration.
Effect of perturbations on VHb insolubilization. Cells bear-
ing the plasmids pRED2, pVDP1, and pVSP1 accumulate very
different levels of VHb, as shown in the SDS-polyacrylamide
gel in Fig. 2. Prior to induction of the vhb promoter, the
protein patterns of the soluble and insoluble fractions of the E.
coli JM1O1::pRED2 (lanes 5 and 6) are very similar to those of
its parent, JM1O1::pUC19 (lanes 3 and 4). Following transfer
to microaerobic conditions, JM1O1::pRED2 accumulates large
quantities of both soluble and insoluble VHb (lanes 7 and 8).
By comparison, JMIOI::pVSP1 produces similar levels of VHb
when induced (lanes 9 and 10) while JM1O1::pVDP1 produces
much lower levels (lanes 11 and 12). The protein patterns of
the different strains expressing VHb under microaerobic con-
ditions are, otherwise, very similar.
The formation of different forms of expressed VHb, namely,
soluble, insoluble, and holo forms, over time in cells bearing
pRED2, pVDP1, and pVSP1 is very different, as shown in Fig.
3. E. coli JM1O1::pRED2 accumulates the majority of its VHb
within 3 h of induction. At this time, most polypeptide is
present in a soluble form, but only approximately 50% contains
heme. Between 3 and 12 h, soluble apoVHb levels decline,
leading to increases in both soluble holoVHb and insoluble
apoVHb levels. After 12 h of cultivation, JM1O1::pRED2
contains approximately 1 ,umol of soluble holoVHb per g (dry
wt), no soluble apoVHb, and 0.5 ,Lmol of insoluble apoVHb
per g (dry wt). Both JM1O1::pVDP1 and JM1O1::pVSP1 also
accumulate the majority of their VHb within 3 h of induction.
Unlike JM1O1::pRED2, however, the formation of VHb spe-
cies in these strains does not change significantly over the
following 9 h of induction. After 12 h of cultivation,
JM1O1::pVSP1 accumulates VHb to a level of approximately
1.7 ,umol/g (dry wt), but only 25% contains heme and is
soluble. In JM1O1::pVDP1, VHb is accumulated to a much
lower level, approximately 0.3 ,umol/g (dry wt) with an insig-
nificant fraction being soluble and containing heme.
Response of VHb solubility to the competitive inhibitor
levulinic acid is expected to be a good indicator of the
sensitivity of insolubilization to heme availability. Levulinic
acid supplementation does not affect the postinduction growth
properties of either E. coli JMIOI::pRED2 or JM1O1::pVDP1
(data not shown). As shown in Fig. 4, however, levulinic acid
does affect soluble holoVHb accumulation in JM1O1::pRED2.
In particular, a monotonic decrease in the level of soluble
holoVHb with increased levulinic acid concentration is ob-
served when the concentration of levulinic acid exceeds 10
mM. Importantly, while the level of soluble holoVHb is
decreased, the levels of soluble VHb and insoluble VHb are
unaffected. Supplementing levulinic acid to JM1O1::pVDP1
cultures, shown in Fig. 5, slightly increases total VHb accumu-
lation but does not affect the accumulation of insoluble VHb.
If the biosynthetic activity of heme in VHb-producing cells is
limited by the ALA synthesis, supplementing this intermediate
should increase flux through the pathway. ALA supplementa-
tion has previously been shown to increase heme biosynthesis
in anaerobically or aerobically grown E. coli when incubated
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FIG. 6. Diagram of heme biosynthetic pathway of E. coli. The intermediates (in boldface type) and their structures, enzymes (in roman type),
and genes (in italic type) required for the conversion of glutamate to heme are shown.
under aerobic conditions (10). As shown in Fig. 4, adding ALA
to JM101::pRED2 cultures has qualitatively the same effect as
adding levulinic acid. At concentrations above 10 mM, ALA is
inhibitory to holoVHb production while it has little effect on
total VHb level or partitioning between soluble and insoluble
forms. Adding ALA to JM101::pVDP1 at concentrations in
excess of 10 mM appears inhibitory to total VHb accumulation
(Fig. 5). Results from supplementing with levulinic acid and
ALA indicate that the level of holoVHb is dependent on heme
levels but that the levels of insoluble apoVHb are not.
DISCUSSION
The pathway governing heme biosynthesis (Fig. 6) is com-
plex and largely conserved among the plant, animal, and
protista kingdoms (1). The most notable difference in the
pathway between different organisms occurs in the synthesis of
ALA. Most facultative aerobic bacteria, including Vitreoscilla
species (2), synthesize ALA by the C4 pathway from succinyl
coenzyme A and glycine (19). E. coli, alternatively, synthesizes
ALA by the C5 pathway from the intact five-carbon chain of
glutamate (19). The enzyme which catalyzes this transforma-
tion, ALA synthase, shows no amino acid homology with any
other cloned ALA synthase (17). Previous studies on wild-type
E. coli suggest that ALA synthesis is the rate-limiting step in
the heme biosynthetic pathway (8, 10). Upon alleviating the
limitation in ALA synthesis, the new limiting step may lie at
porphobilinogen synthesis. ALA dehydratase, the enzyme re-
sponsible for this latter conversion, is competitively inhibited
by levulinic acid (20).
Under hypoxic conditions, Vitreoscilla cells synthesize VHb
polypeptide, NADH-methemoglobin reductase and ALA syn-
thase (2). The increase in ALA synthase levels with VHb
polypeptide synthesis presumably allows the heme biosynthetic
pathway to respond to the greater demand for heme. Expres-
sion of VHb in E. coli leads to increased production of heme
(3, 12). It is not known if this is accomplished by derepression
of heme synthesis or by an amplification of ALA synthase
levels as occurs in Vitreoscilla species.
The results described in this report suggest that ALA
synthesis is not the rate-limiting step of heme biosynthesis in E.
coli strains expressing high levels of VHb. This is evident since
neither enhanced expression of ALA synthase or supplement-
ing medium with ALA leads to significant increases in heme or
soluble holoVHb levels. In fact, ALA supplementation re-
sulted in decreased heme levels and ALA synthase amplifica-
tion led to reduced levels of soluble holoVHb. The general
similarity between these results and those observed with
levulinic acid suggests that increased ALA levels actually
inhibit heme synthesis in strains expressing high levels of VHb.
Spectroscopic analysis clearly shows insoluble VHb uni-
formly lacks heme. Perturbation of heme accumulation with
analysis of VHb accumulation and solubility also shows that
insolubilization is independent of heme availability. This con-
dition is possible, because soluble VHb may or may not contain
stoichiometric levels of heme, depending on the time postin-
duction and culture conditions. Given sufficient time, the
recombinant cells can apparently synthesize sufficient heme to
satisfy soluble VHb stoichiometric requirements. During this
time delay, however, soluble apoVHb, which is known to be
less thermodynamically stable than holoVHb (6), can be partly
insolubilized. Soluble apoprotein was also observed during
optimized expression of human hemoglobin in E. coli from a
synthetic operon composed of a- and P-globin genes (9).
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Further research is required to determine whether these
soluble apoproteins accumulate because of inadequate heme
biosynthesis during high-level globin expression in recombi-
nant E. coli.
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